While the NRF2 Nano-Luc signal increased robustly with MG132 time course in control pre-treated cells, we observed a decreased rate of NRF2 Nano-Luc accumulation in BC-1901S pre-treated cells (Fig. 6C). The gene discussed is NFE2L2; the disease is breast cancer.